109 related articles for article (PubMed ID: 29314780)
21. Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer.
Phaëton R; Gutierrez J; Jiang Z; Karabakhtsian RG; Albanese J; Sunkara J; Fisher DR; Goldberg GL; Dadachova E
Immunotherapy; 2015; 7(6):631-40. PubMed ID: 26098137
[TBL] [Abstract][Full Text] [Related]
22. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
23. HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo.
Hu D; Zhou J; Wang F; Shi H; Li Y; Li B
Arch Gynecol Obstet; 2015 Dec; 292(6):1345-54. PubMed ID: 26093522
[TBL] [Abstract][Full Text] [Related]
24. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.
Yan J; Reichenbach DK; Corbitt N; Hokey DA; Ramanathan MP; McKinney KA; Weiner DB; Sewell D
Vaccine; 2009 Jan; 27(3):431-40. PubMed ID: 19022315
[TBL] [Abstract][Full Text] [Related]
25. Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X.
Illiano E; Bissa M; Paolini F; Zanotto C; De Giuli Morghen C; Franconi R; Radaelli A; Venuti A
Virus Res; 2016 Oct; 225():82-90. PubMed ID: 27664839
[TBL] [Abstract][Full Text] [Related]
26. Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine.
Gan L; Jia R; Zhou L; Guo J; Fan M
PLoS One; 2014; 9(9):e108892. PubMed ID: 25265018
[TBL] [Abstract][Full Text] [Related]
27. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
28. De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin.
Chen S; Liao C; Lai Y; Fan Y; Lu G; Wang H; Zhang X; Lin MC; Leng S; Kung HF
Acta Biochim Biophys Sin (Shanghai); 2014 Jan; 46(1):6-14. PubMed ID: 24240707
[TBL] [Abstract][Full Text] [Related]
29. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
[TBL] [Abstract][Full Text] [Related]
30. Antibody response for L1, E6 and E7 HPV 16 and HPV 18 antigens in Tunisian women with cervical cancer and controls.
Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maalej M; Oueslati R
J Immunoassay Immunochem; 2008; 29(3):266-80. PubMed ID: 18569375
[TBL] [Abstract][Full Text] [Related]
31. DNA vaccine against human papillomavirus type 16: modifications of the E6 oncogene.
Poláková I; Pokorná D; Dusková M; Smahel M
Vaccine; 2010 Feb; 28(6):1506-13. PubMed ID: 20003917
[TBL] [Abstract][Full Text] [Related]
32. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
33. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis.
Ndiaye C; Mena M; Alemany L; Arbyn M; Castellsagué X; Laporte L; Bosch FX; de Sanjosé S; Trottier H
Lancet Oncol; 2014 Nov; 15(12):1319-31. PubMed ID: 25439690
[TBL] [Abstract][Full Text] [Related]
34. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers.
Reuschenbach M; Waterboer T; Wallin KL; Einenkel J; Dillner J; Hamsikova E; Eschenbach D; Zimmer H; Heilig B; Kopitz J; Pawlita M; Doeberitz Mv; Wentzensen N
Int J Cancer; 2008 Dec; 123(11):2626-31. PubMed ID: 18785210
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B surface antigen fusions delivered by DNA vaccination elicit CTL responses to human papillomavirus oncoproteins associated with tumor protection.
Haigh O; Kattenbelt J; Cochrane M; Thomson S; Gould A; Tindle R
Cancer Gene Ther; 2010 Oct; 17(10):708-20. PubMed ID: 20539319
[TBL] [Abstract][Full Text] [Related]
36. DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles.
Ali AA; McCrudden CM; McCaffrey J; McBride JW; Cole G; Dunne NJ; Robson T; Kissenpfennig A; Donnelly RF; McCarthy HO
Nanomedicine; 2017 Apr; 13(3):921-932. PubMed ID: 27979747
[TBL] [Abstract][Full Text] [Related]
37. Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009.
Pellom ST; Smalley Rumfield C; Morillon YM; Roller N; Poppe LK; Brough DE; Sabzevari H; Schlom J; Jochems C
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33651712
[TBL] [Abstract][Full Text] [Related]
38. Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China.
Chenzhang Y; Wen Q; Ding X; Cao M; Chen Z; Mu X; Wang T
Immunol Lett; 2017 Jan; 181():26-30. PubMed ID: 27693214
[TBL] [Abstract][Full Text] [Related]
39. Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine.
de Oliveira LM; Morale MG; Chaves AA; Cavalher AM; Lopes AS; Diniz Mde O; Schanoski AS; de Melo RL; Ferreira LC; de Oliveira ML; Demasi M; Ho PL
PLoS One; 2015; 10(9):e0138686. PubMed ID: 26390407
[TBL] [Abstract][Full Text] [Related]
40. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
